Janssen-Cilag Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia
Links shared publicly online about this topic.
- 1,548total visits
Janssen-Cilag Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia
jnj.com —
Johnson & Johnson news and information regarding our operations, products, leaders, and our charitable giving.
View full resource at jnj.com
Tags: Schizophrenia, Schizophrenia Medication, Psychotic Disorder, Invega Sustenna, Johnson & Johnson, Surgery, News
Most Recently Shared on December 7, 2009 at 5:24 pm By:
Janssen-Cilag Submits EU Application for Paliperidone Palmitate for Trtmnt of Schizophrenia - http://ow.ly/Jzua
Advertisement
